Data refreshed:

Tender WS5872093541-Doc5872241906

ACAN Vaccinia Immunoglobulin intravenous (human) - VIGIV

In plain English

What it is
ACAN Vaccinia Immunoglobulin intravenous (human) - VIGIV
Who's buying
Department of Public Works and Government Services (PSPC)
What they want
Advanced Contract Award Notice(ACAN) - Vaccinia Immunoglobulin intravenous (human) (VIGIV) An ACAN is a public notice indicating to the supplier community that a department or agency intends to award a contract for goods, services or construction to a pre-identified supplier, thereby allowing other suppliers to signal their interest in bidding, by submitting a statement of capabilities. If no supplier submits a statement of capabilities that meets the requirements set out in the ACAN, on or before the closing date stated in the ACAN, the contracting officer may then proceed with the award to t…
Deadline
Sep 30, 2026, 14:00 UTC
How to bid
Submit through CanadaBuys before the deadline, following the instructions in the official notice. Method: Advance contract award notice.
Contact
Ramenason, Anja (SPAC/PSPC) · [email protected]

Notice details

Status
Closed
Solicitation number
WS5872093541
Notice type
Advance Contract Award Notice
Published
Sep 10, 2026
Category (UNSPSC)
Drugs and pharmaceutical products
Regions of delivery
Canada

Similar open tenders

Past awards in this category

  • SO - Naloxone Nasal Spray - Emergent BioSolutions Canada Inc

    CW2464479

    Vendor
    Emergent BioSolutions Canada Inc.
    Value
    $3,000,000
    Awarded
    Aug 20, 2026
  • 21120-268734 Cystic Fibrosis Medications NISO

    CW2448497

    Vendor
    McKesson Canada Corporation
    Value
    $4,000,000
    Awarded
    Apr 10, 2026
  • K4E21-260484 REMOTE MEDICAL HEALTH CARE SUPPORT WITH MEDICAL SUPPLY KITS

    CW2441337

    Vendor
    PRAXES Medical Group
    Value
    $79,147
    Awarded
    Apr 9, 2026
  • Hepatitis B Vaccines Merck

    CW2447092

    Vendor
    Merck Canada Inc.
    Value
    $3,855,797
    Awarded
    Apr 1, 2026
  • Hepatitis B Vaccines GSK

    CW2447088

    Vendor
    GlaxoSmithKline Inc.
    Value
    $9,462,827
    Awarded
    Apr 1, 2026
  • Contract (GSK) - Supply Pertussis-containing vaccines

    CW2445891

    Vendor
    GlaxoSmithKline Inc.
    Value
    $29,400,277
    Awarded
    Mar 30, 2026

Get alerts for tenders like this

One free daily digest. No account needed. Unsubscribe any time.